Terazosin Capsule
Product Images NDC 68788-8171

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 68788-8171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 01)

Chemical structure of terazosin hydrochloride dihydrate, with molecular formula C19H25N5O4 and molecular weight 459.93.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 02)

A data table presenting results from three clinical studies comparing terazosin and placebo. It shows symptom score mean baseline, mean change (percentage), and peak flow rate mean baseline, mean change (percentage) across different doses and study durations, with notes on significance and dosage details.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 03)

Figure 1 from Study 1 presents two line graphs comparing terazosin and placebo. The left graph shows mean change in total symptom score from baseline over 3 months, with terazosin showing a greater decrease than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with terazosin demonstrating a higher increase compared to placebo.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 04)

A line graph depicting the mean change in total symptom score from baseline over 30 months in a long-term, open-label, non-placebo controlled study with 494 participants. The y-axis shows the mean change from baseline, ranging from 0 to -7, while the x-axis represents months from 0 to 30. Data points indicate a decrease in symptom scores, with statistical significance marked at multiple points (p ≤ 0.05 vs. baseline). Mean baseline score is 10.7.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 05)

A line graph showing the mean change in peak flow rate from baseline (mL/sec) over 30 months in a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months, and the y-axis shows mean change from baseline ranging from 0 to 4.5 mL/sec. Data points with statistical significance (p ≤ 0.05) compared to baseline are marked with asterisks. The mean baseline peak flow rate is noted as 9.9.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 06)

A data table titled 'Mean Changes in Blood Pressure from Baseline to Final Visit in all Double-Blind Placebo-Controlled Studies.' It compares systolic and diastolic blood pressure changes (SBP and DBP in mmHg) between placebo and terazosin groups in normotensive patients (DBP ≤ 90 mmHg) and hypertensive patients (DBP > 90 mmHg). Sample sizes (N) and mean changes are shown for each group.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 07)

A data table titled 'Adverse Reactions During Placebo-Controlled Trials Benign Prostatic Hyperplasia' comparing adverse reactions in body systems between terazosin (N=636) and placebo (N=360). It lists percentages of various side effects such as asthenia, dizziness, postural hypotension, and others, categorized by body systems including cardiovascular, digestive, nervous, respiratory, and urogenital. Statistically significant differences marked with an asterisk are noted.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 08)

Table displaying discontinuation rates during placebo-controlled trials of terazosin for benign prostatic hyperplasia. It compares percentages of discontinuations by body system and specific symptoms between terazosin (N=636) and placebo (N=360) groups, including body as a whole, cardiovascular, digestive, nervous, respiratory, special senses, and urogenital systems.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 09)

Table showing adverse reactions during placebo-controlled trials for terazosin versus placebo in hypertension treatment. It lists body systems and specific adverse reactions with their percentage occurrence in both terazosin (N=859) and placebo (N=506) groups. Reactions include asthenia, back pain, headache, palpitations, postural hypotension, nausea, edema, dizziness, somnolence, nasal congestion, blurred vision, and others.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 10)

Table showing discontinuation rates during placebo-controlled trials for hypertension, comparing terazosin (N=859) and placebo (N=506) across various body systems and symptoms including asthenia, headache, cardiovascular issues, digestive problems, metabolic disorders, nervous system effects, respiratory symptoms, and special senses like blurred vision.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 11)

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 12)

FDA Label Image

Terazosin Hydrochloride Capsules 2mg (A78f74ce 1c53 41ea 878e 13674db10a67 00)

Terazosin Hydrochloride Capsules 2 mg label by Heritage Pharma, Inc. d/b/a Avet Pharm. Inc. The label notes the product as generic for Hytrin, with each capsule containing 2 mg terazosin equivalent. Storage instructions specify 20°-25°C, with protection from light and moisture. The capsule is described as white and yellow, imprinted with 736 2mg. Directions for use are provided in English and Spanish on yellow panels, emphasizing use as directed by a doctor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.